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Background and purpose: Access to healthcare data is indispensable for scientific progress and innovation.
Sharing healthcare data is time-consuming and notoriously difficult due to privacy and regulatory con-
cerns. The Personal Health Train (PHT) provides a privacy-by-design infrastructure connecting FAIR
(Findable, Accessible, Interoperable, Reusable) data sources and allows distributed data analysis and
machine learning. Patient data never leaves a healthcare institute.
Materials and methods: Lung cancer patient-specific databases (tumor staging and post-treatment sur-
vival information) of oncology departments were translated according to a FAIR data model and stored
locally in a graph database. Software was installed locally to enable deployment of distributed machine
learning algorithms via a central server. Algorithms (MATLAB, code and documentation publicly avail-
able) are patient privacy-preserving as only summary statistics and regression coefficients are exchanged
with the central server. A logistic regression model to predict post-treatment two-year survival was
trained and evaluated by receiver operating characteristic curves (ROC), root mean square prediction
error (RMSE) and calibration plots.
Results: In 4 months, we connected databases with 23 203 patient cases across 8 healthcare institutes in
5 countries (Amsterdam, Cardiff, Maastricht, Manchester, Nijmegen, Rome, Rotterdam, Shanghai) using
the PHT. Summary statistics were computed across databases. A distributed logistic regression model
predicting post-treatment two-year survival was trained on 14 810 patients treated between 1978 and
2011 and validated on 8 393 patients treated between 2012 and 2015.
Conclusion: The PHT infrastructure demonstrably overcomes patient privacy barriers to healthcare data
sharing and enables fast data analyses across multiple institutes from different countries with different
regulatory regimens. This infrastructure promotes global evidence-based medicine while prioritizing
patient privacy.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 144 (2020) 189–200 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Many current innovations in medicine, including personalized
medicine, artificial intelligence, and decision support systems, rely
on the sharing of data across healthcare providers. Conventionaldata analysis requires sharing and centralization of data to answer
research questions. However, data sharing is hampered by admin-
istrative, political, ethical, and technical barriers [1]. This limits the
amount of healthcare data available for life sciences in general as
well as for other secondary uses such as healthcare quality
assurance.
190 Distributed learning on 20 000+ lung cancer patientsDistributed (machine) learning reformulates conventional data
analysis algorithms so that data centralization becomes unneces-
sary. Consequently, data transfer agreements are not needed. Dis-
tributed algorithms iteratively analyze separate databases and
return the same solution as if data were centralized: essentially
sharing research questions and answers between databases
instead of data.
We are convinced that only sharing research questions (and
answers) between healthcare providers is a better, sustainable
approach to medical data analysis, and can unlock orders of mag-
nitude more data without violating privacy. To this end, we have
developed an infrastructure (see Fig. 1) called the Personal Health
Train [2] (PHT) consisting of
- healthcare sites (‘‘stations”) containing FAIR [3] (Findable,
Accessible, Interoperable, Reusable) data,
- technical network connections and legal frameworks (‘‘tracks”),
- statistical learning applications (‘‘trains”).
A global community of likeminded healthcare providers and
academic partners called CORAL (Community in Oncology for
RApid Learning) was initiated at the 2016 European Society for
Radiotherapy and Oncology (ESTRO) conference. In various
research projects across the globe, CORAL members have worked
on the realization of the PHT.
An infrastructure to bring research questions to the data has
been demonstrated to work recently in projects such as euroCAT
[4,5], DataSHIELD [6] and OHDSI [7]. However, challenges remain
in terms of the number of data subjects, number of data providers,
and global coverage.
The aim of this study is to show that the PHT distributed learn-
ing infrastructure can be scaled to many thousands of patients,
approaching the size of national healthcare registries. Specifically,
we set the goal (as registered on clinicaltrials.gov [8]) to machine
learn a predictive model for post-treatment two-year survival onFig. 1. Personal Health Train infrastructure consisting of a cloud server and network (‘‘more than 20 000 non-small cell lung cancer (NSCLC) patients, in
at least five healthcare providers from more than five countries—
without any patient data leaving a healthcare provider.
Methods
This study was registered on clinicaltrials.gov [8] (https://
www.clinicaltrials.gov/ct2/show/NCT03564457) on 11–06-2018
(first posted date: 20–06-2018, actual study start date: 01–07-
2018). Official project invitations were sent to eight sites on 18–
06-2018 and two additional sites were contacted later but before
the deadline of September 1. Fig. 2 shows the project timeline.
In all participating sites, the project was approved by their insti-
tutional review boards (IRBs) or was conform to national informa-
tion and research governance regulations. Given that the PHT is a
privacy-by-design infrastructure where no individual patient data
leaves the individual healthcare provider, no researcher has access
to the data, data is anonymized or pseudonymized, and given the
number of patients involved, internal privacy officers often felt
informed consent was neither feasible nor necessary.
Patients
Patient cohorts from routine clinical care databases (sites A-B
and D-H) or clinical studies (site C) identified as non-small cell
lung cancer patients were included in this study (Table 1). Data
elements retrieved were
- diagnosis,
- diagnosis date,
- vital status at last follow-up (alive or dead),
- date of last follow-up after the diagnosis date,
and cancer staging as defined by the American Joint Committee
on Cancer [23]:tracks”), hospitals with FAIR data (‘‘stations”), and learning applications (‘‘trains”).
Fig. 2. Project timeline. ESTRO: European Society for Radiotherapy and Oncology.
Table 1
Cohort information. NSCLC: non-small cell lung cancer. SBRT: stereotactic body radiotherapy. RT: radiotherapy. CHART: continuous, hyperfractionated, accelerated radiotherapy.
Disease Interval Treatment
Site A NSCLC Stage I-IV (histologically
confirmed)
January 2008-August 2016 (Chemo-)radiotherapy, surgery, chemotherapy.
Filtered for having last follow-up records in 2018 or documented
vital status.
Site B NSCLC, Stage I-IV, histo-cytologically
confirmed
October 2004-May 2018 (Chemo-)radiotherapy, chemotherapy, surgery, multimodality
treatment.
Site C NSCLC, 1) Peripheral stage I, 2) stage III 1) 2005–2016, 2) 2008–2013 1) SBRT only, 2) concurrent (chemo-)radiotherapy, surgery.
Site D NSCLC Stage I-IV (either clinical diagnosis
or histologically confirmed)
2004–2017 Definitive radiotherapy (55 Gy in 20 fractions, CHART, concurrent
or sequential chemo-radiotherapy or other standard/accepted
radical radiotherapy schedules) excluding SBRT or post-surgery
adjuvant RT.
Site E NSCLC, Stage I-IV (either clinical diagnosis
or histologically confirmed)
1997–2018 First available T, N, and M staging information of lung cancer
patients treated with curative and palliative RT. Includes post-
surgery RT, (chemo-)radiotherapy, recurrences.
Site F NSCLC, Stage I-IV 1982–2018 First available T, N, M, and overall staging information of lung
cancer patients treated with curative and palliative RT. Includes
post-surgery RT, (chemo-)radiotherapy, recurrences.
Site G NSCLC, Stage I-IV 1955–2018 First available T, N, M, and overall staging information of lung
cancer patients. Includes surgery, (chemo-)radiotherapy.
Site H NSCLC, Stage I-IV 1971–2018 First available T, N, M, and overall staging information of all lung
cancer patients treated with curative and palliative RT. Includes
post-surgery RT, (chemo-)radiotherapy, recurrences, SBRT.
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- lymph node (N) stage,
- metastasis (M) stage,
- overall disease stage.
If the diagnosis date was not available, date of first treatment,
date of histology or date of intake were allowed as a surrogate
for the date of diagnosis. Various staging editions (AJCC TNM can-
cer staging editions 1–8) were published and implemented during
the period of treatment. Two-year survival was defined as a
reported time interval between date of diagnosis and date of last
follow-up of more than 2 * 365.24 days with a vital status ‘alive’
at last follow-up or a reported time interval between date of diag-
nosis and date of death of more than 2 * 365.24 days. Two-year
death was defined as date of death less than 730.48 days after
the date of diagnosis. Two-year survival was labelled missing if
date of diagnosis, date of last follow-up, or vital status at last
follow-up were missing. Two-year survival was also defined as
missing if the date of last follow-up was earlier than two years
after the date of diagnosis and the vital status at last follow-up
was ‘alive’ (right-censored).FAIR data model
To make data FAIR, a data model has to be agreed upon between
parties. As per prior work [9] we have implemented this model
using Semantic Web technology. In Fig. S2, a graphical representa-
tion of the model is shown and on github [10] (https://github.com/RadiationOncologyOntology/20kChallenge/wiki) the mapping file
containing the full data model including used classes and proper-
ties can be found. The ‘FAIRness’ of our implementation is
described in the Supplementary Information (Section I).FAIR data stations (‘‘stations”)
Creating FAIR data out of clinical information systems generally
involved the following tools at each institution:
 Source systems: these are the clinical systems in which the data
elements required for this study were stored
 Extract, transform, load (ETL): software to extract data from
source systems, transform data, and load it into a local data
warehouse
 Data warehouse: a local database where data from multiple
source systems (within a single institution) are combined
 Mapping: transformation from the local data warehouse
schema to medical ontologies, e.g., the Radiation Oncology
Ontology [9] (ROO) or the National Cancer Institute thesaurus
[11] (NCIt)
 Graph database: Resource description framework (RDF) data-
base where data elements are FAIR
Table 2 shows an overview of the tools used at the various care
providers. To support the setup of mapping and graph database
software, installation manuals were distributed and remote sup-
port was provided. A tutorial describing how to set up software,
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192 Distributed learning on 20 000+ lung cancer patientsmap data to the required format, and upload it to a local Blaze-
graph endpoint is available on github [10].Network for secure application distribution, execution, and
communication (‘‘tracks”)
For the secure distribution of and messaging between applica-
tions, a solution called the Varian Learning Portal (VLP, Varian
Medical Systems, Palo Alto, CA) was used. The VLP is a cloud-
based system which has implemented user, site, and project man-
agement so that a research project consisting of multiple data pro-
viders and researchers can securely share applications and
communication between applications. To connect the VLP to a local
data station, a learning connector is installed at each data provider.
The learning connector is a gateway through which applications
and communication are handled. The iterative execution of appli-
cations and communication between them is called a learning
run and each data provider can accept or deny each learning run.
All communication and other actions are logged and auditable by
members of a given project.Applications for distributed cohort discovery, and learning (‘‘trains”)
The VLP allows a certificate-based upload of applications. Each
application group has two parts. One that runs at the VLP in the
cloud (master application) and one at each of the sites (site appli-
cation). Multiple application groups were developed in this
project.
 The first application group’s aim is cohort discovery. An applica-
tion is sent to each site to determine and communicate generic
statistics (counts) of the available data in the FAIR data station.
This cohort discovery application includes a SPARQL Protocol
and RDF Query Language (SPARQL) query that can be executed
against the graph database. Each site application reports its site
statistics to a master application running at the VLP which are
then reported back to the researcher who initiated the applica-
tion. Multiple variations of this application group were
employed to generate summary statistics for patient subgroups.
 The second application group aims to train a logistic regression
(LR) model. Each LR site application can, given a SPARQL query,
train a LR model from the local dataset. The regression coeffi-
cients of each site LR model and patient counts are then sent
to the master application that reaches consensus in an iterative
manner. Fig. 3 illustrates the process followed in the LR applica-
tion group.
 The third application group validates a given LR model on the
sites. An application is sent to each site to compute model per-
formance metrics (RMSE, ROC curve, AUC, calibration plots) and
transfers these back to the master application which combines
and passes them on to the researcher. Calibration plots report-
ing calibration-in-the-large and calibration slope are generated
following Steyerberg [13] and include Wilson confidence inter-
vals implemented by Winkler and Nichols [14].
The LR model is trained on patients treated between 1978 and
2012 and validated on all patients treated between 2012 and
2015. Only patients with complete diagnosis date, follow-up date,
follow-up status, and complete T, N, M, and overall stage after
imputation are included. This approach simulates the development
of an LR model and sequential validation on new data becoming
available over time. This is a TRIPOD type 2b validation [15].
The application used to train the LR coefficients in a distributed
manner is based on the Alternating Direction Method of Multipli-
ers (ADMM) and exemplary implementations by Boyd et al.
[16,17]. A short description of ADMM is provided in the Supple-
Fig. 3. A simplified process description of the distributed logistic regression application group. VLP: Varian Learning Portal. ADMM: Alternating Direction Method of
Multipliers. SPARQL: SPARQL Protocol and RDF Query Language.
T.M. Deist et al. / Radiotherapy and Oncology 144 (2020) 189–200 193mentary Information (Section II). For an excellent technical expla-
nation of ADMM, we suggest Boyd et al. [16]. All application groups
are implemented in MATLAB R2018a (Mathworks, Natick, MA).
Code and accompanying documentation are available open-
source [10] (https://github.com/RadiationOncologyOntology/
20kChallenge).Data processing before LR training
The levels for each variable (T, N, M, and overall stage) are
grouped in supercategories (Table 3) to allow regression on data
of different AJCC TNM cancer staging editions and to bundle similar
categories.
Table 3
Supercategories for T, N, M, and overall stages grouping AJCC TNM cancer staging editions 1–8.
T N M Overall stage
0 T0 0 N0 0 M0 0 0
1 T1, T1a, T1b, T1c, T1mi, Tis 1 N1 1 M1, M1a, M1b, M1c 1 IA, IA1, IA2, IA3, IB
2 T2, T2a, T2b 2 N2 X MX II IIA, IIB
3 T3 3 N3 III III, IIIA, IIIB, IIIC
4 T4 X NX IV IV, IVA, IVB
X TX Occult Occult
194 Distributed learning on 20 000+ lung cancer patientsT, N, M, and overall stages were dummy-coded to estimate the
individual effect of each stage on two-year survival. A reference
category was used to avoid multicollinearity issues in the regres-
sion model. The combination T1, N0, M0 and overall stage I was
chosen as the reference because it is arguably the initial lung can-
cer stage. For example, the ordinal variable T stage, which takes six
values (0 to 4, X), is converted to five binary variables representing
T0, T2, T3, T4, TX.Imputation
If a patient misses entries for one or more of the variables T, N,
M, and/or overall staging (but not all of them), imputation of the
missing values is attempted. First, the missing values are logically
induced from the permitted combinations of T, N, M, and overall
stages. If the logical imputation is ambiguous because multiple
imputation results are possible, the missing values are imputed
probabilistically based on a subset of patients from the training
cohort treated at the same site. A detailed imputation process
description is presented in Fig. S3 (Supplementary Information)
and an outline is given in the Supplementary Information
(Section III).Results
In total, eight healthcare providers (‘‘stations”) were contacted
on 18–06-2018 and two additional sites were contacted later. At
the deadline of 01–09-2018 (71 days after the first formal project
invitation), eight sites (in Amsterdam, Cardiff, Maastricht, Manch-
ester, Nijmegen, Rome, Rotterdam, Shanghai) made NSCLC patient
data available in their local database endpoints and two sites did
not participate for logistical reasons: delayed response to first for-
mal invitation in one case and too little time to participate after a
second round of invitations in another case.
A summary statistics application was sent via the Varian Learn-
ing Portal. It computed patient counts for each variable category,
displayed in Table 4. Each site confirmed the validity of the sum-
mary statistics, a quality control step to ensure that correct data
was used for modelling. A total number of 37 090 patients became
available in the system. When restricting the search to patients:
- diagnosed or treated from 01-01-1978 (effective date of the
AJCC TNM cancer staging edition 1) and before 01–01-2016
(allowing at least two years survival follow-up),
- with complete diagnosis date, follow-up date, and follow-up
status (to calculate two-year survival),
the number of available patients decreased to 28 178, which
forms the modelling cohort. Data of patients diagnosed before
2005 were mainly collected by two sites (with minor contributions
from two other sites). Data of patients diagnosed after 2005 were
made available by all sites. Overall, recent data was more abun-
dant. More than half of the modelling data was provided by two
sites: site G (43.0%) and site E (17.0%). Less than 6% of the mod-elling data was sourced from three sites: site D (2.4%), site C
(2.3%), and site B (1.0%).
Histograms for T, N, M, and overall stage categories after bin-
ning into supercategories (Table 3) but before imputation are
shown in Fig. 4. Patients with missing or right-censored two-year
survival are excluded. The percentage of patients alive at two years
differed greatly in the provided data across sites (Fig. 4): from
89.1% in site A to 18.8% in site H. The distribution of T, N, M, and
overall stage categories also varied across sites. Notably, T1 clearly
dominated in sites A and C but other sites display a more balanced
distribution of T categories (Fig. 4a). In sites A-E, N0 is the modal
lymph node category but N2 is most frequent in sites F-H
(Fig. 4b). All sites report most patients in the M0 category but
the decrease in M0 patients correlates loosely with the percentage
of patients alive at two years per site, e.g., site H reports 41.4% M1
compared to 8.8% in site A (Fig. 4c). As a direct consequence of the
differences in T, N, and M category distributions, the overall stage
distribution varies across sites (Fig. 4d).
In general, data completeness is not consistent in the network
(Table 4). Sufficient follow-up information to compute two-year
survival ranges from 92.1% (site D) to 44.1% (site B). Note that
patients with incomplete follow-up (right-censored) have not been
included in the modelling cohort displayed in Fig. 4 and Fig. 5. T, N,
M, or overall stage information is frequently missing in half of the
sites (sites E-H). Overall stage categories are not always reported:
sites E and H do not provide overall stage information. Sites G, F,
and A miss it for 39.8%, 31.8%, and 2.2% of their patients,
respectively.
Based on the temporal distribution of patients in the modelling
cohort, we selected patients from 01-01-1978 until and including
31–12-2011 for training and patients from 01-01-2012 until and
including 31–12-2015 for validation so that we achieved a split
of approximately 2/3 to 1/3 (Fig. 5a).
Only 14 660 patients of 28 178 patients were complete cases (T,
N, M, overall stage, and two-year survival) in the modelling cohort
(Table 6). Imputation did not result in complete cases for some
patients (see methods section for details) yielding a total of 23
203 patients, 14 810 (63.8%) patients for training and 8 393
(36.2%) patients for validation.
The logistic regression application trained a model from the
training data (years 1978–2011) with coefficients as displayed in
Table 5. The convergence criteria of the algorithm are met after
81 iterations (25 minutes). The convergence of the algorithm is dis-
played in Fig. 5b: the root mean square error (RMSE, equivalent to
the Brier score for binary outcomes) for predicting the probability
of two-year survival (left y-axis) in the training cohort decreases
per iteration and approaches 0.42. Although the RMSE has stabi-
lized, not all regression coefficients (right y-axis) have converged.
The validation application assessed the model’s performance on
the validation cohort (years 2012–2015). The validation perfor-
mance is described by the combined RMSE for patients from all
sites (Fig. 5b), the receiver operating characteristic (ROC) curve
per site and their corresponding areas under the curve (AUCs)
(Fig. 5c), and by an exemplary calibration plot of the site with most
patient data provided for training and validation (site G, Fig. 5d).
Table 4
Summary statistics of all patients provided by the sites. These are patient counts before filtering for the modelling cohort (diagnosed in 1978–2015 with available two-year
survival data and at least one stage variable) and before imputation. NSCLC: non-small cell lung cancer.
Site A Site B Site C Site D Site E Site F Site G Site H Site A Site B Site C Site D Site E Site F Site G Site H
Disease Overall stage
NSCLC 5214 706 829 785 6211 4110 16,260 2975 Missing 92 3 0 0 6211 1714 7573 2975
T stage 0 208 0 0 0 0 0 1 0
Missing 4 20 0 0 77 807 6703 10 I 0 0 0 0 0 152 282 0
T0 6 1 0 2 3 36 1 16 IA 2413 93 0 141 0 31 704 0
T1 650 30 34 74 322 429 674 200 IA1 0 0 35 0 0 0 6 0
T1a 1694 82 35 42 337 56 351 78 IA2 0 0 191 0 0 0 36 0
T1b 588 40 191 88 285 96 313 117 IA3 0 0 185 0 0 0 31 0
T1c 0 1 185 0 15 16 73 16 IB 501 48 104 141 0 56 373 0
T2 110 75 39 128 1079 803 2138 844 II 0 0 0 0 0 75 101 0
T2a 1032 92 104 139 772 132 472 91 IIA 459 13 49 65 0 17 135 0
T2b 206 18 49 50 194 65 227 45 IIB 188 56 39 78 0 56 235 0
T3 303 165 77 109 1460 523 1936 518 III 0 0 0 2 0 52 621 0
T4 254 151 107 143 1667 1037 1932 639 IIIA 786 187 110 215 0 348 1689 0
TX 164 31 8 10 0 108 1439 396 IIIB 104 103 116 103 0 577 1753 0
Tis 203 0 0 0 0 2 1 5 IIIC 0 0 0 1 0 1 18 0
N stage IV 199 198 0 39 0 1012 2553 0
Missing 0 20 0 0 14 821 6705 7 IVA 75 0 0 0 0 4 54 0
N0 3649 255 637 384 2756 1041 2830 660 IVB 189 5 0 0 0 15 95 0
N1 520 49 13 153 635 208 598 180 Diagnosis year
N2 777 271 143 215 1835 1132 3510 977 1950–1959 0 0 0 0 0 0 1 0
N3 141 83 36 23 971 810 1437 600 1960–1969 0 0 0 0 0 0 2 0
NX 127 28 0 10 0 98 1180 551 1970–1979 0 0 0 0 0 0 693 1
M stage 1980–1989 0 0 0 0 0 3 2301 362
Missing 2 3 0 0 0 554 6705 4 1990–1999 0 2 0 0 1 16 3192 809
M0 4742 491 829 734 4799 2073 6435 1526 2000–2004 0 5 0 8 1 74 1527 421
M1 87 70 0 8 650 1253 1926 1053 2005 0 18 12 51 223 185 374 83
M1a 92 7 0 11 246 36 164 19 2006 0 15 31 50 313 248 365 78
M1b 285 121 0 20 510 124 497 107 2007 1 24 44 59 276 275 506 68
M1c 1 5 0 0 6 15 107 29 2008 190 123 48 51 314 282 498 95
MX 5 9 0 12 0 55 426 237 2009 214 127 71 42 348 317 528 99
2-year survival 2010 318 92 100 62 401 338 541 125
Missing/Right-censored 614 395 164 62 692 818 3412 477 2011 445 33 117 77 455 306 554 120
No 464 112 258 396 3834 2305 9357 2048 2012 557 32 112 78 626 300 603 121
Yes 4136 199 407 327 1685 987 3491 450 2013 690 34 97 75 692 369 697 100
2014 971 52 31 70 573 345 755 110
2015 1057 43 62 63 641 300 763 112
2016 761 37 103 58 666 302 744 136
2017 0 35 1 41 562 308 607 112
2018 10 11 0 0 118 142 163 23
T.M. Deist et al. / Radiotherapy and Oncology 144 (2020) 189–200 195Calibration plots for all other sites are displayed in Fig. S1 (Supple-
mentary Information). Table 6 summarizes patient counts (avail-
able in the system and in the modelling cohort before and after
imputation) and model performance per site. The validation RMSE
almost-monotonically decreases during optimization on the train-
ing cohort. Discriminative performance of the model (as measured
by the AUC), varies across sites from 0.85 (site A) to 0.58 (site D).
Model calibration in site G is good with a calibration-in-the-large
of 0.02 and calibration-slope of 0.75 but calibration varies strongly
across sites. For example, site A (Supplementary Information,
Fig. S1) displays a calibration-in-the-large of 2.39 and a calibration
slope of 1.09.Discussion
We trained a distributed logistic regression model on 14 810
NSCLC patients and validated it on 8 393 patients from eight sites
worldwide, yielding a total of 23 203 patients. While we thus easily
exceeded the goal of 20 000 by 16.0%, the eight participating sites
originate from only five countries which is one country short of the
intended goal.
Applying FAIR principles in this project highlighted the chal-
lenges in introducing modern data storage and processing
approaches in a clinical research context. Semantic web technology
allows concepts and relationships between concepts to be codedwhich makes data more interpretable – an important FAIR princi-
ple. The use of semantic web technology requires expertise that is
often not present at healthcare institutes. In this project, we
worked closely with all partners to support installations. Future
projects would benefit from user-friendly software assisting
healthcare institutes in transforming their data according to FAIR
principles. Creating such software is the goal of an ongoing
research project in CORAL.
We observed heterogeneity in modelled variables (T, N, M, and
overall stage) and outcome (two-year survival) between sites. Sites
provided different cohort types, either (complete) clinical records
of heterogeneous NSCLC cases or study cohorts with narrower
inclusion criteria which can explain much of this heterogeneity
(Table 1). Specifically, site A had a biased inclusion towards surviv-
ing patients (89.1% two-year survival, Fig. 4) and site C provided
two study cohorts. For both sites, these biases skewed T, N, M,
and overall stage distributions towards lower stages. Even for sites
providing data based on their full clinical records, different model
variable distributions are not surprising since healthcare providers
treat different patient subgroups. For example, data in site F origi-
nates from a radiotherapy clinic while the data in site G is provided
by a comprehensive cancer care center offering different treat-
ments (surgery, (chemo-)radiotherapy, etc.).
For differences in model outcome (two-year survival), there are
multiple (possible) causes. For example, site A experienced a
biased collection of survival information due to its unavailability
Fig. 4. Distributions of T, N, M, and overall stage supercategories (a, b, c, d, respectively) for patients available for training or validation per site (i.e. the modelling cohort)
before selecting for complete cases and imputation. Patients with missing or right-censored two-year survival are excluded. The histograms are separate per site (x-axis) and
split for patients alive and dead at two years after diagnosis (above and below x-axis). Patient counts are normalized per site. The vertical position of the entire bar indicates
the two-year survival ratio of each site.
196 Distributed learning on 20 000+ lung cancer patientsin the healthcare provider’s Electronic Medical Records (EMR) and
the difficulty of retrospectively gathering this missing information
when there is no access to survival registries. Furthermore, some
sites contributed historical data dating back to 1978 where treat-
ment outcomes were generally worse. Additionally, treatment
choices for patient subgroups differ due to national and local treat-
ment guidelines, e.g., patients with metastasized NSCLC.
Heterogeneity throughout the network is generally advanta-
geous for prediction modelling as it allows models to be trained
that are generalizable to a wider range of patients. On the other
hand, if the difference in cohorts is caused by characteristics not
considered by the model, e.g., difference in treatments or data col-
lection biases, then these differences can have a negative effect on
model performance. In our study, site A suffered from a biased
inclusion of surviving patients. The effect on the trained model
should be low as site A only contributed 7.3% of the training cohort
(Fig. 5a). However, the usefulness of this dataset for model valida-
tion is limited because the performance of this model has not been
evaluated for the entire patient population of the site but only for
the subgroup following the biased collection (long survivors or
recent patients, Table 1). A further inclusion bias is present in site
C which provided two study cohorts (predominantly overall stage I
and III) for training and validation. Care has to be taken when inter-
preting validation results: one can only draw conclusions for the
patient subpopulation from which the validation dataset has been
sampled.
Inter-comparison of summary statistics between sites high-
lights significant differences in variable distributions that can thenbe investigated to assure data quality. For example, earlier in this
study, the N stage statistics showed one site to have an excess of
N3 incidence as compared to other sites. This was subsequently
investigated and uncovered a processing error at that site. This role
will become increasingly important as outcome modelling studies
move away from curated clinical trial datasets and towards rou-
tinely collected data and structured information retrospectively
extracted from clinical notes.
We also observed varying model performance between sites:
the validation cohort AUCs ranged from 0.58 (site D) to 0.85 (site
A) and calibration plots (Supplementary Information, Fig. S1) dis-
play obvious differences. Multiple factors might influence stable
performance across sites: e.g., the aforementioned heterogeneity
due to unobserved but important variables, or different staging
practices across sites.
We observe that our results are qualitatively in accordance with
the AJCC TNM cancer staging system: the regression coefficients of
the presented model (Table 5) indicate decreased survival proba-
bilities for increases in T, N, M, and overall stage supercategories
(with exception of T4). For example, the regression coefficients
for overall stage supercategories decrease from 1.05 for overall
stage category 0 to 0.82 for overall stage category IV. Addition-
ally, we quantitatively compared the presented model to the AJCC
TNM cancer staging system: we retrieved two-year survival prob-
abilities for the overall stages IA, IB, IIA, IIB, IIIA, IIIB, IV of the AJCC
TNM cancer staging edition 7[18] (which is the effective edition of
the validation cohort) and predicted two-year survival in the vali-
dation cohort. Patients with overall stages other than IA, IB, IIA, IIB,
Table 5
Logistic regression coefficients per supercategory. T1N0M0 and overall stage category I is the reference category.
Intercept T N M Overall stage
0.93 0 0.96 0 ref. 0 ref. 0 1.05
1 ref. 1 0.01 1 1.09 1 ref.
2 0.69 2 0.19 X 0.00 II 0.19
3 1.08 3 0.67 III 0.76
4 0.87 X 0.54 IV 0.82
X 1.22 Occult 0.37
Fig. 5. (a) The number of patients available for training or validation per year per site. (b) Left axis: root mean square error (RMSE) of logistic regression models optimized on
the training cohort at a given iteration for training and validation cohorts. Right axis: regression coefficients for T, N, M, and overall stage categories computed by the ADMM
algorithm at a given iteration. (c) Receiver operating characteristic curves with area under the curve (AUC) values for the validation cohort per site. (d) Calibration plot of the
validation cohort for site G, the site with most training and validation data. Calibration plots for the remaining sites are displayed in Fig. S1.
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defined or survival probabilities are not reported in TNM edition
7. AUCs of the presented model and the AJCC TNM cancer staging
edition 7 coincided (Supplementary Information, Table S2). A dis-
cussion of other survival prediction models is available in the Sup-
plementary Information (Section IV).
The results demonstrate the capabilities of distributed learning
infrastructures to proffer patient cohorts for statistical analysis.
However, it shall be clearly stated that the presented model
(Table 5) should not be applied in the clinic as this was not the goal
of this study. The modelling methodology could be improved by
explicitly encoding different AJCC staging editions and years of
treatment which would consider improvements in treatmentsand outcomes over four decades. Additionally, employing Cox
regression instead of logistic regression would allow including
right-censored patient data in the analysis.
For this study, we have implemented logistic regression, a tool
popular in statistical analysis and machine learning for its simplic-
ity and interpretability. The presented logistic regression algorithm
is unpenalized. Penalization might help the individual regression
coefficients to converge as it alleviates the multicollinearity prob-
lem (Fig. 5b) and will be explored in future studies. We extend the
list of distributed methods that are already implemented in the
PHT: Bayesian networks [4] and linear support vector machines
[5]. Cox regression, a survival analysis methodology to model more
than one time point, has been implemented previously in a dis-
Table 6
Patient counts and model performance per site. Sites E and H are listed as incomplete as neither site published overall staging data (which may be imputed from T, N and M
stages). AUC: area under the receiver operating characteristic curve. CI: confidence interval using 1000 bootstraps.
Site Available
patients
Modelling cohort patient counts (complete cases, 1978–2015) Model performance
Before imputation After imputation Training Validation
Training Validation Total Training Validation Total AUC 95%-CI AUC 95%-CI Calibration-
in-the-large
Calibration
slope
Site A 5214 1050 3024 4074 1084 3058 4142 0.79 [0.75, 0.82] 0.85 [0.83, 0.87] 2.39 1.09
Site B 706 203 87 290 204 87 291 0.71 [0.62, 0.77] 0.67 [0.54, 0.78] 1.04 0.62
Site C 829 390 260 650 390 260 650 0.62 [0.57, 0.67] 0.63 [0.57, 0.69] 0.36 0.59
Site D 785 398 276 674 398 276 674 0.61 [0.55, 0.66] 0.58 [0.51, 0.64] 0.07 0.40
Site E 6211 0 0 0 2265 2458 4723 0.70 [0.68, 0.72] 0.73 [0.70, 0.75] 0.09 0.85
Site F 4110 1165 520 1685 1906 1017 2923 0.73 [0.71, 0.76] 0.74 [0.71, 0.77] 0.20 0.96
Site G 16,260 6414 873 7287 6803 889 7692 0.74 [0.73, 0.75] 0.71 [0.68, 0.75] 0.02 0.75
Site H 2975 0 0 0 1760 348 2108 0.74 [0.71, 0.77] 0.75 [0.68, 0.80] 0.43 0.76
Total 37,090 9620 5040 14,660 14,810 8393 23,203
198 Distributed learning on 20 000+ lung cancer patientstributed setting [19]. Distributed learning approaches for other
popular machine learning methods are available for future imple-
mentation, e.g., (convolutional) neural networks [20].
An alternative to the PHT is DataSHIELD [21], a mature open-
source distributed data analysis and machine learning platform
with multiple applications. It is based on the open-source software
R and Opal data warehouses. The PHT infrastructure differentiates
itself from DataSHIELD in multiple aspects:
- it is not limited to R but is compatible with multiple languages
(e.g., Java, MATLAB, C#, Python, R),
- it offers analytical flexibility by not limiting the researcher to a
fixed function library (DataSHIELD v4.0 comprises 140 R func-
tions [21]),
- it uses Semantic Web technology to store and query data at
sites but also allows relational databases and SQL queries.
The presented PHT study only considers a very limited number
of clinical data elements (T, N, M, overall stage, diagnosis year, sur-
vival follow-up). Arguably, individual predictions need many more
data elements. Additional clinical (e.g., age, comorbidities), biolog-
ical (e.g., genomics, proteomics), imaging (e.g., screening, radio-
mics [22]) and treatment sources (e.g., radiotherapy treatment
planning) are likely to contain relevant data elements for the pre-
diction of a survival outcome. Furthermore, the two-year survival
outcome is not sufficient for clinical decision support: quality-of-
life, toxicity and cost are also relevant for a balanced decision to
be taken. However, due to the limited number of data elements
required for inclusion, we could reach very high inclusion numbers
and could show that the methodology of distributed learning
scales to these numbers. Although the data quality is improving
in routine care, the more data elements a study requires, the less
complete datasets will be available. As quality improves, future
studies are possible where additional data elements (not only
prognostic but also predictive for treatment outcomes) can be
included and thus better and more clinically relevant models can
be developed using the proposed infrastructure.
The PHT enables machine learning studies on more data: more
data is generally preferable over too little data. Combining data
from multiple institutes, however, comes with challenges faced
by any multi-institutional machine learning study (regardless
whether it was conducted via a distributed infrastructure or in data
centralization projects). Model performance can vary across
cohorts (Table 6) or models trained on individual cohorts may per-
form better. These and other, unexpected results could have differ-
ent causes, e.g., unobserved confounding factors or different
outcome collection standards. Multi-institutional machine learn-
ing studies will require a clear methodology to a priori identify
and afterwards report on such causes. Experience from and tech-niques used for clinical trial designs should form the basis for such
methodology.
This project shows distributed learning infrastructures are cap-
able of delivering cohort sizes to rival those available to research-
ers from national registries. However, distributed approaches such
as the PHT, where each institute must only satisfy its local informa-
tion and research governance requirements, ease the bureaucratic
burden of learning from internationally separated pools of
patients, particularly between countries with differing information
governance regimes. Furthermore, the system is much more flexi-
ble and makes including additional data elements into analyses a
simple process. If an item is not present in a registry dataset, retro-
spectively adding this information to previous years is very diffi-
cult if not logistically impossible. Lastly, the infrastructure
provides a mechanism to expedite the external validation of prog-
nostic and predictive models in cohorts from different countries
with different patient demographics, organizational cultures, and
treatment regimens.
This study has shown that distributed machine learning using
Semantic Web technology can be implemented in a short time
frame to answer specific research questions. In future work, we
will extend CORAL with more cancer centers and include more
data elements noted in routine care (we invite all interested parties
to contact the corresponding author). As new patients and data ele-
ments become available, we expect that the PHT will enable
researchers to rapidly train new prediction models: accelerating
the speed at which clinical observations are turned into actionable
knowledge.
The Personal Health Train infrastructure was deployed across
eight healthcare institutes in five countries in four months. A
two-year survival prediction model was trained and validated in
more than 20 000 non-small cell lung cancer patients. This infras-
tructure demonstrably overcomes patient privacy barriers to
healthcare data sharing and implements distributed data analysis
and machine learning across healthcare providers worldwide.Conflict of interest
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